A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis

Trial Profile

A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms BREEZE-AD3
  • Sponsors Eli Lilly
  • Most Recent Events

    • 09 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top